Business
CareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society
Over 25 Abstracts Highlight Value of AlloSure and AlloSeq cfDNA BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™
About this update from Caredx, Inc.
[{"type":"text","content":"\nOver 25 Abstracts Highlight Value of AlloSure and AlloSeq cfDNA\n\n BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading participation in the 29th International Congress of The Transplantation Society (TTS 2022) taking place September 10-14 in Buenos Aires, Argentina.\n\nTransplant physicians will present data from over 25 abstracts demonstrating the value of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and AlloSeq cfDNA in clinical practice, and emerging trends and innovation in transplantation, including artificial intelligence and the potential use of CareDx’s molecular testing services for xenotransplantation surveillance.\n\n“As the transplant innovation leader, CareDx is thrilled to expand its presence globally with data from over 25 abstracts being presented at this internationally renowned TTS congress,” said Reg Seeto, CEO and President of CareDx. “We also look forward to sharing information about the next wave of innovation focused on the latest AiKidney™ and AiCAV™ developments.”\n\nDr. Alexandre Loupy, Paris Transplant Group, added, “I look forward to attending the meeting and discussing how artificial intelligence is transforming patient care by helping physicians tailor plans based on a patient’s risk profile for rejection and post-transplant complications.”\n\nAbout CareDx – The Transplant Company\n\nCareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.\n\nForward-Looking Statements\n\nThis press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s leading participation in the 29th International Congress...